CD19-Specific CAR T-Cell Therapy Effective in Ibrutinib-Refractory CLL – Cancer Network
|
CD19-Specific CAR T-Cell Therapy Effective in Ibrutinib-Refractory CLL
Cancer Network Anti-CD19 chimeric antigen receptor (CAR)-modified T–cell therapy was highly effective in patients with high-risk chronic lymphocytic leukemia (CLL) who had previously failed treatment with ibrutinib, according to the results of a study published in … |
